Search Results - technology+classifications+%3e+therapeutic+%3e+cell+and+gene+therapies

6 Results Sort By:
IRF4-Engineered T Cells Induce T Cell Function As a Treatment Strategy for Solid Tumors
Asset/Technology Type New Therapeutic Strategy Description of Invention The invention includes compositions and methods of delivering therapeutic anti-tumor T cells by forcing them to overexpress interferon regulatory factor (IRF4) as a treatment for various solid tumors, including but not limited to melanoma, lymphoma, and colon cancer. The inventors...
Published: 4/11/2025   |   Inventor(s): Wenhao Chen, Xian Li
Keywords(s):  
Category(s): Clinical Area > Transplantation, Clinical Area > Cancer, Clinical Area > Metabolic Disease, Inflammation, and Immunology, Research Area > Cancer, Research Area > Immunobiology and Inflammation, Technology Classifications > Therapeutic > Cell and Gene Therapies
Modulating the AIBP-CAV1-VEGFR3 axis to treat lymphatic disorders
This invention is a method of promoting lymphangiogenesis in order to treat lymphatic disorders, namely lymphedema and Alzheimer’s disease (AD). VEGFC-induced VEGFR3 signaling is the major driver of lymphangiogenesis, however the distinct molecular mechanisms determining how VEGFR3 signaling controls lymphatic endothelial cell (LEC) fate remains...
Published: 3/12/2024   |   Inventor(s): Longhou Fang, Jun-dae Kim
Keywords(s):  
Category(s): Clinical Area > Metabolic Disease, Inflammation, and Immunology, Clinical Area > Neurology, Clinical Area > Cardiovascular, Research Area > Heart and Vascular, Research Area > Immunobiology and Inflammation, Research Area > Neurology and Neurosurgery, Technology Classifications > Therapeutic > Cell and Gene Therapies, Technology Classifications > Therapeutic > Small Molecules, Technology Classifications > Therapeutic > Biologics
Aptamer-engineered Natural Killer Cells for Adaptive Immunotherapy
The invention is a unique technology to engineer Natural Killer (NK) cells with synthetic oligonucleotide aptamers for tumor cell-specific cancer immunotherapy. Stage of Development In vitro Study: The aptamer-engineered NK (ApEn-NK) cells could be generated via a simple one-step process in minutes. The generated ApEn-NK cells were able to specifically...
Published: 10/7/2024   |   Inventor(s): Youli Zu
Keywords(s):  
Category(s): Clinical Area > Cancer, Research Area > Cancer, Clinical Area > Metabolic Disease, Inflammation, and Immunology, Technology Classifications > Therapeutic > Cell and Gene Therapies
A DNAzyme that targets the CAG repeat RNA in polyglutamine diseases
The invention is a synthetic single-stranded DNA molecule that functions as a specific RNA-cleaving DNA enzyme (or DNAzyme) as a potential therapeutic for the treatment of polyglutamine diseases. The binding arms of this synthetic DNAzyme are complementary to the CAG repeats found in the pathological expansion of CAG trinucleotide repeats in the translated...
Published: 12/24/2024   |   Inventor(s): Nan Zhang, Tetsuo Ashizawa
Keywords(s):  
Category(s): Clinical Area > Neurology, Research Area > Neurology and Neurosurgery, Technology Classifications > Therapeutic > Cell and Gene Therapies
SREBP2 Inhibitors for Treating T-Cell Acute Lymphoblastic Leukemia
This invention is a method of inhibiting sterol regulatory element-binding protein 2 (SREBP2) in order to treat, prevent, reverse, and/or ameliorate conditions associated with an improper number of hematopoietic stem and progenitor cells (HSPCs). SREBP22 is traditionally known as a transcription factor that plays a role in cholesterol homeostasis. However,...
Published: 3/12/2024   |   Inventor(s): Longhou Fang, Qilin Gu
Keywords(s):  
Category(s): Technology Classifications > Therapeutic > Small Molecules, Technology Classifications > Therapeutic > Cell and Gene Therapies, Clinical Area > Cancer, Research Area > Cancer
PSMA-Targeted CAR-T Therapy for Castration-Resistant Prostate Cancer
This invention includes ten novel PSMA-targeted CAR-T therapies to treat castration-resistant prostate cancer. The CAR-T constructs were generated using scFvs from five different mouse hybridomas. We have further enhanced the lead PSMA-targeted CAR-T therapy by co-expressing IRF4 to regulate effector T cell activity and tissue infiltration. The co-expression...
Published: 10/1/2024   |   Inventor(s): Bin He
Keywords(s):  
Category(s): Technology Classifications > Therapeutic > Biologics, Technology Classifications > Therapeutic > Cell and Gene Therapies, Clinical Area > Cancer, Research Area > Cancer